
    
      The overall study aim is to provide real world evidence (RWE) on the characteristics,
      clinical management, treatment outcomes and healthcare resource use of adult patients aged 18
      years and older admitted to the hospital for CAP or cSSTI who received ZinforoÂ® in a usual
      care setting in Europe and Latin America on or before 31-May-2019.
    
  